Last reviewed · How we verify

AP611074 5% gel

Vaxart · Phase 2 active Small molecule

AP611074 5% gel is a Small molecule drug developed by Vaxart. It is currently in Phase 2 development for Investigational immunomodulatory indication (specific indication not publicly disclosed).

AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin.

AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin. Used for Investigational immunomodulatory indication (specific indication not publicly disclosed).

At a glance

Generic nameAP611074 5% gel
SponsorVaxart
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 2

Mechanism of action

AP611074 is a 5% gel formulation developed by Vaxart for topical application. As a phase 2 candidate, it is intended to modulate immune function at the site of application, potentially enhancing antiviral or anti-tumor immunity through local immune activation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AP611074 5% gel

What is AP611074 5% gel?

AP611074 5% gel is a Small molecule drug developed by Vaxart, indicated for Investigational immunomodulatory indication (specific indication not publicly disclosed).

How does AP611074 5% gel work?

AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin.

What is AP611074 5% gel used for?

AP611074 5% gel is indicated for Investigational immunomodulatory indication (specific indication not publicly disclosed).

Who makes AP611074 5% gel?

AP611074 5% gel is developed by Vaxart (see full Vaxart pipeline at /company/vaxart).

What development phase is AP611074 5% gel in?

AP611074 5% gel is in Phase 2.

Related